Zobrazeno 1 - 10
of 2 874
pro vyhledávání: '"SUBTILISIN/KEXIN TYPE 9"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Observational studies suggest dyslipidemia as an atopic dermatitis (AD) risk factor and posit that lipid-lowering drugs may influence AD risk, but the causal link remains elusive. Mendelian randomization was applied to elucidate the causal r
Externí odkaz:
https://doaj.org/article/5b624e49267646ceb4c9d61063934cce
Autor:
CHEN Renliang, CHEN Fengying
Publikováno v:
Zhongguo linchuang yanjiu, Vol 37, Iss 6, Pp 826-829 (2024)
Coronary heart disease (CHD) is currently an important cause of mortality among residents in China and worldwide. The incidence of CHD in China is increasing annually. Among the various factors leading to the occurrence of CHD, abnormalities in blood
Externí odkaz:
https://doaj.org/article/58e1a145ddbf4d2fb99b144da5b37dc2
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Melanoma proliferation is partly attributed to dysregulated lipid metabolism. The effectiveness of lipid-lowering drugs in combating cutaneous melanoma (CM) is a subject of ongoing debate in both in vitro and clinical studies. Met
Externí odkaz:
https://doaj.org/article/525964663de24daf8fe030b98848ab0a
Autor:
Yanyan Zhang, Zhaohui Pei, Beijian Chen, Yanling Qu, Xiaolin Dong, Binge Yu, Guoqin Wang, Fang Xu, Dongmei Lu, Zhimei He, Benchao Chen, Lei Ma, Max Wang, Baiyong Li, Michelle Xia, Bo Zheng, Yong Huo
Publikováno v:
Pharmacological Research, Vol 207, Iss , Pp 107340- (2024)
Randomized clinical trials (RCTs) of PCSK9 monoclonal antibody(mAb) specifically for Chinese patients have been limited. This multi-center RCT is to clarify the efficacy and safety of a novel mAb, Ebronucimab, in Chinese patients. Patients diagnosed
Externí odkaz:
https://doaj.org/article/34cb6dc3117e4e9588ec6a9afed8ef2b
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
Recent clinical trials demonstrated that proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors reduce cardiovascular events without affecting systemic inflammation in the patients with coronary artery disease, as determined by high sensitivity
Externí odkaz:
https://doaj.org/article/3e447212c28f4950be5249f5829f0f08
Autor:
Khursheed Muzammil, Mohammad Hosseini Hooshiar, Shirin Varmazyar, Thabit Moath Omar, Manal Morad Karim, Sadeq Aadi, Shaylan Kalavi, Saman Yasamineh
Publikováno v:
Microbial Cell Factories, Vol 23, Iss 1, Pp 1-22 (2024)
Abstract Cellular lipid membranes serve as the primary barrier preventing viral infection of the host cell and provide viruses with a critical initial point of contact. Occasionally, viruses can utilize lipids as viral receptors. Viruses depend signi
Externí odkaz:
https://doaj.org/article/4a6f0dca0f2b4e3f93039385058e11d9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Milan Gupta, Rajvi J. Wani, Khalid Al Faraidy, Jean Bergeron, Eduardo Contreras, Angel Alberto Garcia Peña, G. B. John Mancini, Francisco Padilla, Abel Alberto Pavia Lopez, Kiran Philip, Johnny Wu, Erin S. Mackinnon
Publikováno v:
Cardiology and Therapy, Vol 12, Iss 4, Pp 703-722 (2023)
Abstract Introduction This study characterizes patients receiving evolocumab in clinical practice and assesses treatment effectiveness, safety and persistence outcomes across five countries. Methods This retrospective and prospective observational st
Externí odkaz:
https://doaj.org/article/871e335605904a328cdc04840034dac7
Publikováno v:
Xin yixue, Vol 54, Iss 10, Pp 712-716 (2023)
Objective To evaluate the efficacy and safety of evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in lowering LDL-C levels in patients with coronary heart disease complicated with mild renal insufficiency. Method
Externí odkaz:
https://doaj.org/article/43b258ac53f448cb8ff37a54cf3b619c
Autor:
Renata Rajtar-Salwa, Beata Bobrowska, Sylwia Socha, Artur Dziewierz, Zbigniew Siudak, Jakub Batko, Stanisław Bartuś, Agata Krawczyk-Ożóg
Publikováno v:
Medicina, Vol 60, Iss 7, p 1124 (2024)
Background and Objectives: Lowering low-density lipoprotein (LDL-C) levels is critical for preventing atherosclerotic cardiovascular disease, yet some patients fail to reach the LDL-C targets despite available intensive lipid-lowering therapies. This
Externí odkaz:
https://doaj.org/article/4300a8a6fb674fc08ba17a92afc0f2fa